Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Exelixis is a commercial-stage oncology company focused on kidney and liver cancers, with cabozantinib (Cabometyx/Cometriq) as its flagship asset generating approximately $1.8B+ in annual revenue. The company operates a hybrid model combining proprietary US commercialization with ex-US partnerships (Ipsen, Takeda) while advancing a pipeline of kinase inhibitors targeting solid tumors. Strong cash generation ($800M+ FCF) and minimal debt position the company to self-fund clinical development while returning capital through share repurchases.
Exelixis generates revenue primarily through direct US commercialization of cabozantinib in advanced kidney and liver cancers, capturing 96%+ gross margins on product sales. The company leveraged partnerships to monetize ex-US markets without building international infrastructure, receiving double-digit royalties on partner sales plus milestone payments. Pricing power derives from cabozantinib's differentiated efficacy profile in second-line renal cell carcinoma and first-line hepatocellular carcinoma, with limited direct competition in these specific settings. The company reinvests approximately 25-30% of revenue into R&D to expand cabozantinib's label and advance pipeline assets (zanzalintinib, XL092) targeting additional solid tumor indications.
Cabozantinib US net product revenue growth and market share trends in RCC/HCC - particularly penetration in first-line HCC and combination therapy adoption
Clinical trial readouts for pipeline assets (zanzalintinib in biliary tract cancer, XL092 in solid tumors) and label expansion opportunities for cabozantinib
Collaboration revenue volatility from partner milestone achievements and ex-US sales performance (Ipsen European sales trends)
Capital allocation decisions including share repurchase authorization utilization and potential business development activity
Competitive dynamics in RCC/HCC including CheckMate-9ER uptake, TKI/IO combination data, and emerging targeted therapies
Patent cliff risk for cabozantinib with composition of matter patents expiring 2030-2032, creating generic/biosimilar erosion threat within 5-7 years absent successful pipeline development
Evolving treatment paradigms in RCC/HCC with increasing adoption of IO/IO combinations and novel targeted agents potentially displacing TKI monotherapy market share
Pricing pressure from Medicare negotiation authority under IRA (cabozantinib likely subject to negotiation post-2028 given revenue scale) and international reference pricing dynamics
Bristol-Myers Squibb's CheckMate-9ER (nivolumab/cabozantinib) success creates channel conflict as BMS promotes its own IO/TKI combination, potentially limiting Exelixis's ability to expand cabozantinib monotherapy share
Emerging competition in HCC from Roche (atezolizumab/bevacizumab), Eisai/MSD (lenvatinib/pembrolizumab), and AstraZeneca (durvalumab/tremelimumab) in first-line setting
Pipeline execution risk with zanzalintinib and XL092 facing crowded solid tumor landscapes requiring differentiated efficacy/safety profiles for commercial success
Minimal financial risk given strong balance sheet with $2B+ cash, negligible debt, and positive operating cash flow generation
Capital allocation risk if business development pursuits (acquisitions, licensing) destroy value or if share repurchases occur at inflated valuations
low - Oncology drug demand is highly inelastic and driven by disease incidence rather than economic conditions. Cancer diagnosis and treatment decisions are non-discretionary, insulating revenue from GDP fluctuations. However, severe recessions could pressure healthcare budgets and payer reimbursement negotiations, though impact would be delayed and modest given specialty oncology positioning.
Rising rates create modest headwinds through higher discount rates applied to future pipeline value, compressing valuation multiples for biotech stocks. However, Exelixis's strong current profitability and cash generation reduce sensitivity compared to pre-revenue biotechs. The company holds $2B+ in cash/investments generating higher yields in rising rate environments, partially offsetting valuation pressure. Minimal debt ($100M) means negligible direct financing cost impact.
Minimal - Company maintains investment-grade balance sheet with 3.5x+ current ratio and negligible debt. Does not rely on credit markets for operations or growth. Payer credit quality could theoretically affect receivables, but diversified payer mix and government program exposure (Medicare/Medicaid) limit concentration risk.
growth - Attracts growth-oriented investors seeking exposure to commercial-stage biotech with established revenue base, strong cash generation, and pipeline optionality. The 30%+ net margins and 7%+ FCF yield appeal to GARP (growth at reasonable price) investors. Lack of dividend limits pure income investors, while the 60% EPS growth and 30% 1-year return attract momentum players. Institutional ownership is high given the $11.9B market cap and S&P MidCap 400 inclusion.
moderate-to-high - Biotech sector typically exhibits elevated volatility with beta around 1.2-1.5x market. Stock moves significantly on clinical trial data releases, FDA decisions, and competitive developments. However, established revenue base and profitability reduce volatility versus pre-revenue biotechs. Options market typically prices 35-45% implied volatility, reflecting binary clinical/regulatory event risk overlaid on commercial execution uncertainty.
